Review of the Brazilian Guidelines for Cervical Cancer Screening, 2016

Katz, Leticia

doi:10.5935/1676-2444.20160034

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the Brazilian Cervical Cancer Guidelines, all cases with cytological findings of ASC-H, HSIL and CC should be analyzed by colposcopy and histology, before being properly treated and/or having a follow-up [ 59 ]. At colposcopy, cervical samples were collected with a cytobrush, immediately suspended in 1 ml of sterile 0.9% NaCl solution and frozen at −80 °C until analyzed.…”

Section: Methodsmentioning

confidence: 99%

Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer

Bahls

Yamakawa

Zanão

et al. 2017

IJMS

View full text Add to dashboard Cite

Only a small proportion of women who are exposed to infection with high-risk human papillomavirus (HR-HPV) progress to persistent infection and develop cervical cancer (CC). The immune response and genetic background of the host may affect the risk of progression from a HR-HPV infection to lesions and cancer. However, to our knowledge, no studies has been conducted to evaluate the relationship between variability of human leukocyte antigens (HLA) genes and serum cytokine expression in this pathology. In the current study, we examined the associations of HLA alleles and haplotypes including Class I (HLA-A, -B and -C) and II (HLA-DRB1, -DQA1 and -DQB1) with serum levels of cytokines interleukin (IL)-6, tumor necrosis factor-α (TNF-α), IL-10 and IL-17 as well as risks of HPV infections, lesions and CC among admixed Brazilian women. HLA polymorphisms were associated with an increased risk or protection from HPV, lesions and CC. Additionally, we demonstrated a potential association of a HLA class I haplotype (HLA-B*14-C*08) with higher IL-10 cytokine serum levels in cervical disease, suggesting an association between HLA class I and specific cytokines in cervical carcinogenesis. However, larger studies with detailed HPV types coupled with genetic data are needed to further evaluate the effects of HLA and CC by HPV genotype.

show abstract

Section: Methodsmentioning

confidence: 99%

Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer

Bahls

Yamakawa

Zanão

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…Cytology is still the most common national cervical cancer screening method, despite the difficulty implementing them in low-resource settings (i.e. without trained gynaecologists and pathologists, and laboratory facilities) [41]. In this regard, HPV DNA testing offers several advantages over cytology for expanding screening with limited resources to hard-to-reach populations.…”

Section: Modern Screening Methods To Overcome Disparitiesmentioning

confidence: 99%

Universal cervical cancer control through a right to health lens: refocusing national policy and programmes on underserved women

Perehudoff

Vermandere

Williams

et al. 2020

BMC Int Health Hum Rights

View full text Add to dashboard Cite

Background: Cervical cancer claims 311,000 lives annually, and 90% of these deaths occur in low-and middleincome countries. Cervical cancer is a highly preventable and treatable disease, if detected through screening at an early stage. Governments have a responsibility to screen women for precancerous cervical lesions. Yet, national screening programmes overlook many poor women and those marginalised in society. Under-screened women (called hard-to-reach) experience a higher incidence of cervical cancer and elevated mortality rates compared to regularly-screened women. Such inequalities deprive hard-to-reach women of the full enjoyment of their right to sexual and reproductive health, as laid out in Article 12 of the International Covenant on Economic, Social and Cultural Rights and General Comment No. 22. Discussion: This article argues first for tailored and innovative national cervical cancer screening programmes (NCSP) grounded in human rights law, to close the disparity between women who are afforded screening and those who are not. Second, acknowledging socioeconomic disparities requires governments to adopt and refine universal cancer control through NCSPs aligned with human rights duties, including to reach all eligible women. Commonly reported-and chronically under-addressed-screening disparities relate to the availability of sufficient health facilities and human resources (example from Kenya), the physical accessibility of health services for rural and remote populations (example from Brazil), and the accessibility of information sensitive to cultural, ethnic, and linguistic barriers (example from Ecuador). Third, governments can adopt new technologies to overcome individual and structural barriers to cervical cancer screening. National cervical cancer screening programmes should tailor screening methods to under-screened women, bearing in mind that eliminating systemic discrimination may require committing greater resources to traditionally neglected groups.

show abstract

Review of the Brazilian Guidelines for Cervical Cancer Screening, 2016

Cited by 2 publications

References 0 publications

Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer

Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer

Universal cervical cancer control through a right to health lens: refocusing national policy and programmes on underserved women

Contact Info

Product

Resources

About